PP
KLRS

PDT Partners’s Kalaris Therapeutics KLRS Stock Holding History

PDT Partners’s Portfolio KLRS Stock Details KLRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-870
Closed -$158K – 933
2022
Q3 		$158K Sell
870
-578
-40% -$90.1K 0.02% 749
2022
Q2 		$130K Buy
1,448
+135
+10% +$14.2K 0.01% 870
2022
Q1 		$204K Buy
+1,313
New +$262K 0.02% 812

Other funds holding KLRS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Alkeon Capital Management
Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

PDT Partners's KLRS Position: Q4 2022 in Review

PDT Partners sold out of Kalaris Therapeutics (KLRS) in Q4 2022, closing a stake of 870 shares — an estimated $158K sold.

PDT Partners first reported a position in KLRS in Q1 2022 and held it in 3 quarters. The position peaked at $204K in Q1 2022. 85 funds tracked by Wall St. Rank hold KLRS as of Q4 2022.

  • PDT Partners reported no remaining Kalaris Therapeutics position as of Q4 2022 after selling out during the quarter.
  • PDT Partners sold 870 Kalaris Therapeutics shares in Q4 2022, an estimated $158K.
  • PDT Partners first reported a position in Kalaris Therapeutics in Q1 2022 and held it in 3 quarters.
  • PDT Partners's Kalaris Therapeutics position peaked at $204K in Q1 2022.
  • 85 funds tracked by Wall St. Rank held Kalaris Therapeutics as of Q4 2022.

Based on PDT Partners's 13F filing for Q4 2022, filed 14 Feb 2023.